Skip to main content
Participant, Site Personnel and Sponsor Perspectives on Decentralized Trial Features in COURAGE-ALS: a Randomized Clinical Trial
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
Hospitalizations as an Outcome Measure in COURAGE-ALS
A Plain Language Summary of the SEQUOIA-HCM Study: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The Effect of Omecamtiv Mecarbil on Outcomes Analysed Using the Win Ratio: an Exploratory Analysis of GALACTIC-HF
Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region
Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms
Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy